King's College London: Data will allow King’s College London (KCL) to locate patients and invite them to participate in a study called STRATA.

Data-sharing agreement from NHS Digital registers of approved data releases, 2014–2019. Evidence status: source reported.

Organisation: King's College London
Source reference: DARS-NIC-309328-R9V1C-v1.2
Jurisdiction: England
Licence: Open Government Licence v3.0, subject to NHS England terms and exclusions

Register reference: DARS-NIC-309328-R9V1C-v1.2
Agreement period: not published to no end date published
For commercial purposes (as marked in the register): Not stated
Release files listed by NHS England: 2

Data approved

MRIS - List Cleaning Report

Objective, as published

Data will allow King’s College London (KCL) to locate patients and invite them to participate in a study called STRATA. The patients were originally involved in a study called AESOP and were recruited into the study in 1998-1999 at one of two sites (Nottingham and South East London). AESOP recruited first episode psychosis studies to investigate the epidemiological factors relating to first episode psychosis in a cohort representative of the local population. Informed consent was taken for AESOP, and while it was not standard practice at that time to take consent for re-contact, the Section 251 approval permits KCL to contact patients who did not explicitly give consent to be contacted about future studies. The objective of STRATA is to explore the predictors of treatment-resistant schizophrenia. Previous studies examining treatment-resistance have recruited patients with chronic schizophrenia and have therefore been biased towards more treatment-resistant patients. STRATA includes only first episode patients to minimise this bias. STRATA will therefore have proportions of treatment-resistant and treatment-responsive patients who reflect those found in the general population of schizophrenia patients. However, as it can take an average of four years to determine whether a patient is treatment-resistant, STRATA is including first episode studies where the patients have been followed up for some time. The most recent AESOP follow up time point was 10 years. Some patients were…

Expected benefits, as published

While the use of list cleaning data will not have any immediate benefits to health and/or social care, the data obtained from patients who consent to take part in the study could lead to considerable advancements in the care of patients with schizophrenia within 5-10 years. Identifying a stratifier of treatment resistance in schizophrenia could allow clinicians to identify medication more suited to their patients, far more quickly than current clinical practice. This could save some patients many years in hospital on medication which has considerable side effects and is not the best medication strategy for them.

Source: https://webarchive.nationalarchives.gov.uk/ukgwa/2019/http://content.digital.nhs.uk/media/22305/Data-Release-Register-April-to-August-2016/xls/Data_Release_Register__April_-_August_2016.xlsx. Captured 2026-10-30.

Limitations: Agreement as recorded in an NHS Digital register of approved data releases (2014–2019), retrieved from the UK Government Web Archive. That register lists releases made in its period and the agreement's purpose statement as it then stood; it gives no agreement dates, and the agreement may have changed since. Imported only where a paper quotes a reference no current register holds.